Destiny Pharma Share Discussion Threads

[supracat] 03/8/2020 08:13

I could only get 2500 at the open. Tried for another 25000 but kept being told no, or phone broker.

[wh1spa] 03/8/2020 08:09

Either a glitch but can't buy anything - not even £500 worth - with two separate brokers.....

[supracat] 02/8/2020 09:02

Ty. They've had ups and downs along the way, mostly delays versus the plan which damaged sentiment and trust I think. The business has low overheads and is moving along nicely now. Hopefully the FDA concession, further grant funding, and a rapid 2b outcome will give a significant share price boost in coming weeks. Here's hoping.

[supracat] 02/8/2020 09:00

Who is chatting to themselves?? First sign of insanity....

[supracat] 02/8/2020 08:59

Ty. My 25k buy at 33..... is showing as a sell though. It was definitely a buy. Very sneaky if they are trying to disguise it as a sell.....

[wh1spa] 01/8/2020 22:26

Really gets on my wick when multiple aliases start chatting to themselves.....

[wh1spa] 31/7/2020 23:13

Thanks Tole - I did think that Advfn used to list it and then promptly thought i was losing my marbles!
From my point of view I'm looking to ditch L2 as the order book is fairly inaccurate for small cap stuff - dummy trades seem to give a better idea where we are at. Sometimes it's of interest if I see more market makers joining as it can indicate potential movement/ change of sentiment.

[tole] 31/7/2020 22:25

If you don't have level2 there are a few places you can find it for free.Advfn used to publish it on the share fundamentals information but for whatever reason that was removed.A few other brokers/fund manages display the EMS information in their share factsheets. Use fidelity.co.ukJust search for the share you want and view the fact sheet and it is listed in the data.Listed as 1500 for Destiny Pharma.

[gb904150] 31/7/2020 19:03

Thank you Wh1spa. That's a helpful article.

I wasn't sure if it's possible to see the EMS anywhere for free - but it appears not unless you're happy to shell out for Level 2.

[wh1spa] 31/7/2020 18:15

Apologies NMS is now known as EMS. Good level 2 providers should list it.https://aim-watch.com/project/definition-exchange-market-size/

[gb904150] 31/7/2020 17:47

Hi Wh1spa, what is the easiest way to find the NMS of a share?

I picked up some of these for the first time today.

Like the prudent use of cash, funded to Q4 2021, strong insider ownership, AMR focus, new AMR action fund. Seems the timing is good on a risk/reward basis with the phase 2b trials coming up.

[wh1spa] 31/7/2020 17:09

Above NMS so they delayed reporting.

[supracat] 31/7/2020 17:03

Sneaky MMs..... That 25k sale today was actually my 25k buy earlier this afternoon , one of a few buys today.

[tarlok] 31/7/2020 15:53

timing is everything....normally you get the "panicked" sells when you see price here...but not one sell fell for it.... (DEST share holders are made of sterner stuff ! ) so MM now move price up....and was looking for the sign to buy ,so now i have increased my position

[supracat] 31/7/2020 15:51

Bit strange as two of my larger trades, one is 25k not appearing in the trades list so far....

[supracat] 31/7/2020 15:49

Taken my holding up over 500k today with more buys, like these shares a lot.

[hedgehog 100] 31/7/2020 15:34

Excellent post Wh1spa, thanks.

Tarlok, I think you may have spoken too soon!

Looks like DEST could be in for its first blue day since July 7th.

[tarlok] 31/7/2020 08:00

So the classic MM trap , as is the case on small AIM stocks , 99 % buys all week ,no price change up . one MM on ask all week so "looks" like a rise is immanent and now no sells and look at open price , the price drops ..classic

[wh1spa] 29/7/2020 10:18

Well I've bought in today. Just 25,000 shares but will add in the near future. As soon as peeps jump off the Covid bandwagon and realise AMR is more of an underlying threat - coupled with the fact that novel drugs/ approaches are needed urgently then they will no doubt turn up. Glad to see recent fund set up - it's a shame it's taken this awful pandemic to make governments sit up and start to think on a preventative level.

[tole] 28/7/2020 12:46

FinnCap update yesterday Destiny Pharma (DEST): CorpPhase 2b update – FDA agreed amendment – positiveThe agreement with the FDA to amend the Phase 2b trial of its lead drug, XF-73, partly due to COVID disruption, is a positive development. Not only does it reduce the number of patients needed in the trial, but it should ensure that the trial completes enrolment by year-end 2020, without compromising the power or quality of the study; in doing so, preserving the potential of the trial results towards the Phase 3 clinical trial. We remain very excited about this programme, given the support from the FDA and national guidelines that actively recommend decolonisation (eradication of S.aureus bacteria) prior to high-risk surgery despite the lack of an approved treatment in the US. We reiterate 250p TP.

[hedgehog 100] 27/7/2020 09:54

27/07/2020 07:00 UKREG Destiny Pharma PLC Update on Phase 2b clinical study of XF-73

Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections

Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value

Study two thirds enrolled. Recruitment now expected to complete by year end

Planned study interim safety review to be announced in August 2020

Brighton, United Kingdom - 27 July 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel treatments for hospital infections that address the global challenge of antimicrobial resistance (AMR), is pleased to announce a clinical protocol amendment has been agreed with FDA for its ongoing phase 2b study of lead asset XF-73.

The study is evaluating XF-73, as a nasal gel, for the prevention of post-surgical hospital infections caused by Staphylococcus aureus bacteria, such as MRSA. The agreed amendment recognizes the impact COVID-19 has had in slowing patient recruitment in clinical studies since March and the FDA's willingness to support certain protocol amendments that help to accelerate the completion of ongoing clinical trials but do not compromise a study's integrity and clinical objectives.

The amendment to the protocol incorporates a change to the primary patient population where the primary endpoint for the study will be measured. The primary microbiological endpoint post-surgery will now be measured in those patients who had a positive load of nasal Staphylococcus aureus before receiving the study treatment. This contrasts to the original primary population, which included all randomised patients regardless of their baseline nasal load of Staphylococcus aureus. Very importantly, this change enables a reduction in the prospectively defined study size from 200 patients to 125 while maintaining the statistical power of the study and its clinical value. This preserves the potential of the trial results to be a key step towards the Phase 3 clinical trial programme of XF-73. Destiny Pharma has informed all appropriate regulatory bodies and ethics committees involved. Other protocol modifications agreed with the FDA regarding study procedures will also make it easier for hospitals to recruit and retain hospital patients.

Destiny Pharma expects that as the incidence of COVID-19 continues to decline in European hospitals they will begin recruiting patients into the study again and that recruitment into US study sites is likely to lag, given the higher infection incidence. That said, the study has already enrolled 77 patients out of the new target of 125 and the Company expects to have over 20 sites open in three countries actively recruiting the remaining patients in the next few months with the majority of these being FDA-compliant sites in Europe. The study remains on track to complete recruitment by the end of 2020. The result of a planned interim safety review by the study's Independent Safety Monitoring Board is expected to be announced in August 2020.

Neil Clark, Chief Executive Officer of Destiny Pharma, commented:

"We are very pleased to have agreed the protocol amendment with the FDA. The changes will help us complete recruitment later in 2020 and still be well placed to move towards Phase 3 clinical studies if the Phase 2b results are positive. Destiny Pharma is funded through to the last quarter of 2021 and remains confident in the clinical need and significant commercial opportunity for its lead clinical asset XF-73 as a novel preventive treatment of serious hospital infections".

[fillipe] 27/7/2020 08:49

Also today, finnCap reiterate a 250p target price.
I'm surprised this isn't flying, although guess that many folks are much aware of the company.

f